xanomeline/trospium (KarXT) / BMS 
Welcome,         Profile    Billing    Logout  
 0 Diseases   4 Trials   4 Trials   59 News 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
xanomeline/trospium (KarXT) / BMS
2022-001515-10: A Phase 3 study to assess the safety of KarXT and how it helps in reoccurrence prevention in people with psychosis associated with Alzheimer’s Disease Dementia as compared to placebo Un estudio de fase 3 para evaluar la seguridad de KarXT y cómo ayuda aprevenir la recurrencia en personas con psicosis asociada con la demenciapor enfermedad de Alzheimer en comparación con un placebo

Not yet recruiting
3
380
Europe, RoW
KarXT, [--], [n/a], Capsule, hard
Karuna Therapeutics, Karuna Therapeutics, Inc., Karuna Therapeutics, Karuna Therapeutics, Inc.
Psychosis Associated with Alzheimer’s Disease Dementia Psicosis asociada con la demencia de la enfermedad de Alzheimer, Delusions or hallucinations associated with mild to severe Alzheimer’s disease memory loss Delirios o alucinaciones asociados con la pérdida de memoria leve agrave de la enfermedad de Alzheimer, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2022-001666-35: A rollover study for subjects that complete Kar-012, to assess Long-term Safety and Tolerability of KarXT in combination with specified atypical antipsychotics in Subjects with Inadequately Controlled Symptoms of Schizophrenia

Not yet recruiting
3
280
Europe
KarXT, Capsule, hard
Karuna Therapeutics, Inc., Karuna Therapeutics, Inc.
Schizophrenia, Brain disorder that causes altered state that affects a person's ability to think, feel, and behave clearly., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2022-001665-12: A Phase 3 study to assess the safety and effectiveness of KarXT in combination with specific approved atypical antipsychotic medications to reduce the signs and symptoms of Schizophrenia in adult subjects.

Not yet recruiting
3
400
Europe
KarXT, Capsule, hard
Karuna Therapeutics, Inc., Karuna Therapeutics, Inc.
Schizophrenia, brain disorder that causes altered state of affect a person's ability to think, feel, and behave clearly., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
PENNANT, NCT05643170: An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

Terminated
3
4
US
Xanomeline and Trospium Chloride Capsules
Karuna Therapeutics
Schizophrenia
03/23
03/23
NCT04659174: An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Checkmark 52-week open label trial initiation in adults with schizophrenia
Feb 2021 - Feb 2021: 52-week open label trial initiation in adults with schizophrenia
Completed
3
156
US, RoW
Xanomeline and Trospium Chloride Capsules, KarXT
Karuna Therapeutics
Schizophrenia
10/23
10/23
ADEPT-2, NCT06126224: A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease

Recruiting
3
400
Europe, Canada, US, RoW
KarXT, Placebo
Karuna Therapeutics
Psychosis Associated With Alzheimer's Disease
07/25
07/25
EMERGENT-5, NCT04820309: An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia

Checkmark Initiation of EMERGENT-5 study in patients with schizophrenia
Jun 2021 - Jun 2021: Initiation of EMERGENT-5 study in patients with schizophrenia
Completed
3
568
US
Xanomeline and Trospium Chloride Capsules, KarXT
Karuna Therapeutics
Schizophrenia
05/24
05/24
ADEPT-4, NCT06585787: A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease

Recruiting
3
406
Europe, US, RoW
KarXT, BMS-986510, Placebo
Karuna Therapeutics
Alzheimer Disease
10/26
11/26
NCT05145413: A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Checkmark Initiation of ARISE trial in adults with schizophrenia
Jan 2022 - Jan 2022: Initiation of ARISE trial in adults with schizophrenia
Recruiting
3
400
Europe, Japan, US, RoW
Xanomeline and Trospium Chloride Capsules, Placebo
Karuna Therapeutics
Schizophrenia
02/25
02/25
NCT06572449: Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

Not yet recruiting
3
100
US
KarXT, BMS-986510
Karuna Therapeutics
Schizophrenia
08/25
08/25
ADEPT-1, NCT05511363: A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease

Recruiting
3
380
Europe, US, RoW
KarXT, Placebo
Karuna Therapeutics
Psychosis Associated With Alzheimer's Disease
10/26
10/26
UNITE-001, NCT05919823: A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

Recruiting
3
158
RoW
Xanomeline and Trospium Chloride Capsules, KarXT, Placebo
Karuna Therapeutics, Zai Lab (Shanghai) Co., Ltd.
Schizophrenia
05/25
05/25
NCT05304767: An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Recruiting
3
280
Europe, Japan, US, RoW
Xanomeline and Trospium Chloride Capsules
Karuna Therapeutics
Schizophrenia
02/26
02/26
ADEPT-3, NCT05980949: Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease

Recruiting
3
300
Europe, Canada, US, RoW
KarXT
Karuna Therapeutics
Psychosis Associated With Alzheimer's Disease
04/26
04/26
CN012-0030, NCT06605950: A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

Not yet recruiting
1
78
US
KarXT, BMS-986510, Xanomeline/Trospium Chloride, KarX-EC, BMS-986519, Xanomeline Enteric-coated, Placebo, Omeprazole
Karuna Therapeutics
Healthy Volunteers
04/25
04/25

Download Options